Nxera Pharma Inks Exclusive PIVLAZ™ Distribution Deal with Handok in South Korea


Understood. I will provide an SEO-optimized article based on the given context, using proper HTML formatting tags suitable for a WordPress post. I will include only the article content in my output, without the title or any extra commentary.

Nxera Pharma Co. Ltd, through its operating business Nxera Pharma Korea, has signed an exclusive supply and distribution agreement with Handok Inc. for the commercialization of PIVLAZ™ 150 mg in the South Korean market. This strategic partnership aims to expand the availability of PIVLAZ™, a promising therapeutic solution, to patients in South Korea.

Under the terms of the agreement, Nxera Pharma will be responsible for the supply of PIVLAZ™ 150 mg, while Handok Inc. will leverage its extensive distribution network and market expertise to ensure the product reaches healthcare providers and patients throughout South Korea. The collaboration between the two companies is expected to accelerate the accessibility of this innovative treatment option in the region.